COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel (LEVEQ-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01096485
Recruitment Status : Completed
First Posted : March 31, 2010
Last Update Posted : June 11, 2013
Information provided by:

Brief Summary:
A single dose, two treatments (Postday and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 21 days between the two study periods. Treatment groups were balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.

Condition or disease Intervention/treatment Phase
Contraception Contraception, Postcoital Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion) Drug: Levonorgestrel (Postday) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Open-label, Randomized, Crossover Study to Compare the Bioavailability of One Coated Tablet of Opxion® (Levonorgestrel 1.5 mg From Bayer de Mexico) vs. Two Tablets of Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers
Study Start Date : February 2009
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Arm Intervention/treatment
Experimental: Arm 1 Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Single dose of 1.5 mg coated tablet

Active Comparator: Arm 2 Drug: Levonorgestrel (Postday)
Single dose of two 0.75 mg tablets

Primary Outcome Measures :
  1. Least square estimator of average maximum plasmatic concentration (log transformed) [ Time Frame: After 2 months ]
  2. Least square estimator of area under the pharmacokinetic curve (log transformed) [ Time Frame: After 2 months ]

Secondary Outcome Measures :
  1. Time at which maximum concentration is reached [ Time Frame: After 2 months ]
  2. Area under the pharmacokinetic curve from time=0 to time of last blood sample [ Time Frame: After 2 months ]
  3. Clearance constant of plasmatic concentration of study drug [ Time Frame: After 2 months ]
  4. Half life of plasmatic concentration of study drug [ Time Frame: After 2 months ]
  5. Adverse events collection [ Time Frame: Up to 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis.

Exclusion Criteria:

  • History of illnesses or any organic abnormalities that could affect the results of the study.
  • History of abuse tobacco or alcohol or regular use of recreational or therapeutic drugs.
  • Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01096485

Layout table for location information
Morelia, Michoacán, Mexico, 58256
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Medical Director, Bayer de Mexico S.A. de C.V. Identifier: NCT01096485    
Other Study ID Numbers: 13956
First Posted: March 31, 2010    Key Record Dates
Last Update Posted: June 11, 2013
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral